News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Genomics Company Illumigen Biosciences, Inc. Completes $12 Million Recap Round
April 28, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
4/28/2006 – Hoping to harness the properties of beneficial genetic mutations for new therapies, Illumigen Biosciences Inc. closed a $12 million recapitalization, which includes about $8 million in new money, VentureWire has learned.
Twitter
LinkedIn
Facebook
Email
Print
Startups
MORE ON THIS TOPIC
IN PARTNERSHIP WITH EVOTEC
Strategic Drug Development in a Funding Crisis: Expert Insights on Risk Profiling, Efficiency, and Innovation
October 13, 2025
·
8 min read
·
BioSpace Insights
Drug pricing
AstraZeneca Becomes Second Pharma to Strike DTC Deal With Trump Administration
October 10, 2025
·
1 min read
·
Dan Samorodnitsky
Layoff Tracker
Ferring To Cut 500 Employees as Part of Business Model Shift
October 10, 2025
·
70 min read
·
BioSpace Editorial Staff
Mergers & acquisitions
BMS Makes $1.5B Cell Therapy Play With Orbital Takeover
October 10, 2025
·
2 min read
·
Tristan Manalac
